Magda Conradie

Magda Conradie

Auto-generated profile, based on publicly available information

Magda Conradie

Private practice, Durban, South Africa

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 February 2015 in Archives of Osteoporosis
Verified
Journal Article
Closed access
PDF file
MCMagda Conradie
Magda Conradie
MCMaria M. Conradie
Maria M. Conradie
ASAlan T. Scher
Alan T. Scher
MKMartin Kidd
Martin Kidd
SHStephen Hough
Stephen Hough

5 September 2014 in Archives of Osteoporosis
Verified
Journal Article
Closed access
PDF file
MCMagda Conradie
Magda Conradie
MCMaria M. Conradie
Maria M. Conradie
MKMartin Kidd
Martin Kidd
SHStephen Hough
Stephen Hough

26 May 2021 in Climacteric
Verified
Journal Article
Closed access
MCM. Conradie
M. Conradie
TVT. de Villiers
T. de Villiers
In premenopausal women, bone mineral density measurement by dual-energy X-ray absorptiometry should not be used as the sole guide for diagnosis or treatment of osteoporosis, universal screening with bone mineral density is not advised and the World Health Organization classification of bone status should not be applied. A diagnosis of premenopausal osteoporosis is reserved for those with evidence of fragility and may also be considered in women with low bone mass and an ongoing secondary cause of osteoporosis. Idiopathic osteoporosis in young women is rare. A thorough evaluation of secondary causes is indicated in all patients, with glucocorticoid treatment a common secondary cause of low bone mass and osteoporosis. Hypoestrogenism may be the primary cause of low bone mass and contribute to excessive bone loss in many conditions associated with premenopausal osteoporosis, and should be treated unless contra-indicated. The mainstay of treatment in premenopausal females with low bone mass includes risk factor reduction, advocating a healthy, active lifestyle and optimal treatment of secondary causes of bone loss. The safety of bone-specific therapy, especially long term and during pregnancy, remains uncertain. Bisphosphonates, teriparatide, denosumab and estrogen treatment increase bone density in premenopausal women with osteoporosis, but there are no study data confirming short-term fracture prevention with use of these agents.

1 March 2021 in Archives of Osteoporosis
Verified
Journal Article
Open access
PDF file
HJHelena Johansson
Helena Johansson
SDSapna S. Dela
Sapna S. Dela
BCBilkish Cassim
Bilkish Cassim
FPFarhanah Paruk
Farhanah Paruk
SBSusan L. Brown
Susan L. Brown
JKJohn A. Kanis
John A. Kanis
Summary The hip fracture rates in South Africa were used to create ethnic-specific FRAX® models to facilitate fracture risk assessment. Introduction The aim of this study was to develop FRAX models to compute the 10-year probability of hip fracture and major osteoporotic fracture and assess their potential clinical application. Methods Age- and sex-specific incidence of hip fracture and national mortality rates were incorporated into a FRAX model for the White, Black African, Coloured and Indian population of South Africa. Age-specific 10-year probabilities of a major osteoporotic fracture were calculated in women to determine fracture probabilities at a femoral neck T score of -2.5 SD, or those equivalent to a woman with a prior fragility fracture. Fracture probabilities were compared with those from selected countries. Results Probabilities were consistently higher in Indian than in Coloured men and women, in turn, higher than in Black South Africans. For White South Africans, probabilities were lower than in Indians at young ages up to the age of about 80 years. When a BMD T score of −2.5 SD was used as an intervention threshold, FRAX probabilities in women age 50 years were approximately 2-fold higher than in women of the same age but with an average BMD and no risk factors. The increment in risk associated with the BMD threshold decreased progressively with age such that, at the age of 80 years or more, a T score of −2.5 SD was no longer a risk factor. Probabilities equivalent to women with a previous fracture rose with age and identified women at increased risk at all ages. Conclusions These FRAX models should enhance accuracy of determining fracture probability amongst the South African population and help guide decisions about treatment.

15 June 2017 in Frontiers in Immunology
Verified
Journal Article
Open access
LKLéanie Kleynhans
Léanie Kleynhans
SRSheena Ruzive
Sheena Ruzive
LELizaan Ehlers
Lizaan Ehlers
LTLani Thiart
Lani Thiart
NCNovel N Chegou
Novel N Chegou
KRKatharina Ronacher
Katharina Ronacher
A bidirectional communication between the immune and endocrine systems exists and facilitates optimum responses in the host during infections. This is in part achieved through changes of secretion patterns of hypothalamic hormones induced by inflammatory cytokines. The aim of this study was to elucidate the immune-endocrine alterations during TB treatment in patients with cured and failed TB treatment outcomes. Blood samples were collected from 27 cured and 10 failed patients and hormone as well as cytokine concentrations quantified at baseline, week 4 and month 6 of TB treatment. Hormone profiles of the two treatment outcome groups were different from each other prior to as well as during TB treatment. Treatment response effects were observed for cortisol, estradiol, T3, T4 ghrelin, leptin, amylin, adiponectin and DHEA. Trends suggest that T4, amylin and DHEA concentrations were different between treatment outcomes, although these did not reach statistical significance. Relationships between endocrine and inflammatory markers and the biological pathways involved differed between cured and failed treatment patients. These results highlight the complex interaction between the endocrine and immune system during active TB disease and throughout treatment and suggest that endocrine markers in conjunction with inflammatory markers may be useful in predicting unfavorable treatment outcomes.

5 June 2019 in Journal of Endocrinology, Metabolism and Diabetes of South Africa
Verified
Journal Article
Open access
ACAnkia Coetzee
Ankia Coetzee
ABAmanda Beukes
Amanda Beukes
RDReinhardt Dreyer
Reinhardt Dreyer
SSSalaamah Solomon
Salaamah Solomon
LWLourentia van Wyk
Lourentia van Wyk
MVMari van de Vyver
Mari van de Vyver
Objectives: To assess the contribution of traditional and modifiable risk factors to the overall risk and prevalence of type 2 diabetes mellitus (T2DM) amongst health workers (HWs) in the public sector. Design: A retrospective analysis was performed on data obtained from 260 participants. Setting and subjects: HWs at Tygerberg Hospital, Western Cape attending the World Diabetes Day (WDD) metabolic screening and educational event. Outcome measures: The 10-year risk stratification for T2DM was calculated in all HWs attending the WDD event. This was based on the Finnish ‘Test2prevent’ diabetes risk calculator endorsed by the International Diabetes Federation assessing a set of well-established metabolic risk factors. Self-reported consumption of sugar-sweetened beverages (SSBs) was added to the questionnaire but did not add to the risk calculation. Results: The prevalence of known hyperglycaemia in this cohort is concerning (11%, n = 62). An additional 29 health workers were identified as at high risk to develop T2DM within 10 years. Consumption of SSBs and minimal physical activity were identified as modifiable targets for intervention. Conclusions: Education and lifestyle interventions are of paramount importance to ensure the metabolic health of HWs and their communities. Policies and guidelines focused on limiting unhealthy/obesogenic work environments are urgently needed.